|3.15|| -0.05 / -1.56%|
Tenax Therapeutics, Inc. engages in developing biotechnology products, which focuses on oxygen delivery to specific target tissues. The company has developed a proprietary perfluorocarbon therapeutic oxygen carrier called Oxycyte that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke. It is also developing PFC-based creams and gels for topical delivery to the skin for dermatologic conditions and potentially wound care. In addition, the company has commercialized its Dermacyte line of skin care cosmetics for the anti-aging market. Tenax Therapeutics was founded on May 26, 1967 and is headquartered in Morrisville, NC.
|John P. Kelley||Chief Executive Officer & Director|
|Michael B. Jebsen||Chief Financial Officer & Treasurer|
|Timothy Bradshaw||Executive Vice President-Clinical Development|
|Paula Bokesch||Chief Medical Officer|
|Doug Randall||Executive VP-Business & Commercial Operations|